Enterprise Value
156.2M
Cash
33.04M
Avg Qtr Burn
-5.542M
Short % of Float
12.40%
Insider Ownership
11.99%
Institutional Own.
9.05%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details Genetic disorder, Rare genetic disease | Approved Update | |
Elelyso® (taliglucerase alpha) Details Genetic disorder, Rare genetic disease | Approved Quarterly sales | |
PRX-115 Details Chronic refractory gout | Phase 1 Data readout | |
Alidornase alfa (PRX-110) Details Genetic disorder, Rare genetic disease, Cystic fibrosis | Failed Discontinued | |
OPRX-106 Details Inflammatory disease, Bowel disorder | Failed Discontinued |